Risk Factors for Chest Pain and Fever in Patients Undergoing Pleurodesis with OK-432

Objective In Japan, pleurodesis is often performed using OK-432. However, OK-432 may cause severe chest pain and fever. The risk factors for these complications are unclear. The aim of this study was to identify the risk factors for chest pain and fever caused by pleurodesis with OK-432. Methods The clinical data of 94 patients who underwent pleurodesis with OK-432 were retrospectively analyzed. Patients who developed chest pain (indicated by a record of rescue pain medication) and/or fever (a recorded temperature of >38℃) were identified. A logistic regression analysis was performed to determine the risk factors for these complications. Results Rescue medication for chest pain was required by 43.6% of the patients and 40.4% developed pyrexia after pleurodesis with OK-432. The univariate analysis showed that the likelihood of requiring rescue medication for chest pain was significantly increased in patients of <70 years of age (p=0.028) and in those who were not premedicated with a nonsteroidal anti-inflammatory drug (NSAID; p=0.003). Age <70 years (adjusted odds ratio 2.97, 95% confidence interval 1.10-8.00, p=0.031) and a lack of premedication with an NSAID (adjusted odds ratio 4.21, 95% confidence interval 1.47-12.04, p=0.007) remained significant factors in a multivariate analysis. The absence of NSAID premedication was the only statistically significant risk factor for fever in the univariate analysis (p=0.034). The multivariate analysis revealed no significant risk factors for fever. Conclusion The results of the present study suggest that premedication with an NSAID might be useful for preventing the chest pain caused by pleurodesis with OK-432. Furthermore, caution is advised when managing chest pain in adults of <70 years of age. Prospective studies should be performed to further investigate this issue.

[1]  Anoop Chauhan,et al.  Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial. , 2015, JAMA.

[2]  Jang-Ming Lee,et al.  Chemical pleurodesis for prolonged postoperative air leak in primary spontaneous pneumothorax. , 2014, Journal of the Formosan Medical Association = Taiwan yi zhi.

[3]  M. Soudack,et al.  Nonsteroidal Antiinflammatory Medications: Efficient and Safe Treatment Following Video-Assisted Pleurodesis for Spontaneous Pneumothorax , 2011, World Journal of Surgery.

[4]  W. C. Yu,et al.  Minocycline and talc slurry pleurodesis for patients with secondary spontaneous pneumothorax. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  N. Saijo,et al.  Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. , 2007, Lung cancer.

[6]  P. Kvale,et al.  Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[7]  T. Treasure,et al.  Using non-steroidal anti-inflammatory drugs (NSAIDs) following pleurodesis. , 2006, Interactive cardiovascular and thoracic surgery.

[8]  S. Neragi-Miandoab,et al.  Malignant pleural effusion, current and evolving approaches for its diagnosis and management. , 2006, Lung cancer.

[9]  K. Nishi,et al.  Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer. , 2006, Anticancer research.

[10]  T. Miyazawa,et al.  Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non‐small cell lung cancer , 2006, Respirology.

[11]  O. Lesur,et al.  Signal transduction and functional changes in neutrophils with aging , 2004, Aging cell.

[12]  P. Linton,et al.  Age-related changes in lymphocyte development and function , 2004, Nature Immunology.

[13]  T. Morisaki,et al.  Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. , 1996, Clinical immunology and immunopathology.

[14]  K. Matsushima,et al.  Induction of inflammatory cytokines in the pleural effusion of cancer patients after the administration of an immunomodulator, OK-432: role of IL-8 for neutrophil infiltration. , 1993, Cytokine.

[15]  T. Miyazawa,et al.  Talc pleurodesis for the management of malignant pleural effusions in Japan. , 2013, Internal medicine.

[16]  M. Raza Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010 , 2011 .